{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:33:18Z","timestamp":1792794798626,"version":"4.5.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,12]]},"abstract":"<jats:sec>\n            <jats:title>Objects:<\/jats:title>\n            <jats:p>Human bladder cancer (BC) is the most common urogenital system malignancy. E2F transcription factors (E2Fs) have been reported to be involved in the growth of various cancers. However, the expression patterns, prognostic value and immune infiltration in the tumor microenvironment of the 8 E2Fs in BC have yet fully to be explored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and strategy:<\/jats:title>\n            <jats:p>We investigated the differential expression of E2Fs in BC patients, the prognostic value and correlation with immune infiltration by analyzing a range of databases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We found that the mRNA expression levels of E2F1\/2\/3\/4\/5\/7\/8 were significantly higher in BC patients than that of control tissues. And the increased mRNA expression levels of all E2Fs were associated with tumor stage of BC. The survival analysis revealed that the elevated mRNA expression levels of E2F3\/5\/8 were significantly correlated with the overall survival (OS) of BC patients. And the genetic changes of E2Fs in BC patients were associated with shorter overall survival (OS) and progression-free survival (PFS). In addition, we revealed that the E2F3\/5\/8 expressions were closely correlated with tumor-infiltrating lymphocytes (TILs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>E2F3\/5\/8 might serve as promising prognostic biomarkers and new therapeutic direction for BC patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035722","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T20:01:39Z","timestamp":1705089699000},"page":"e35722","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["E2F3\/5\/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer"],"prefix":"10.1097","volume":"103","author":[{"given":"Zhilu","family":"Gan","sequence":"first","affiliation":[{"name":"Surgery Department of Urology, The Third People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimujiang","family":"Abudurexiti","sequence":"additional","affiliation":[{"name":"Surgery Department of Urology, The Third People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Hu","sequence":"additional","affiliation":[{"name":"Surgery Department of Urology, The Third People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Surgery Department of Urology, The Third People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[{"name":"Surgery Department of Urology, The Third People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, P.R. China"},{"name":"Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40880-015-0001-2","article-title":"Annual report on status of cancer in China, 2011.","volume":"27","author":"Chen","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","article-title":"The multifaceted immune regulation of bladder cancer.","volume":"16","author":"Schneider","year":"2019","journal-title":"Nat Rev Urol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-9-3","article-title":"Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.","volume":"9","author":"Kim","year":"2010","journal-title":"Mol Cancer"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ijc.29352","article-title":"Comprehensive characterization of the genomic alterations in human gastric cancer.","volume":"137","author":"Cui","year":"2015","journal-title":"Int J Cancer"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clinbiochem.2018.11.009","article-title":"Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.","volume":"64","author":"Stasik","year":"2019","journal-title":"Clin Biochem"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1038\/sj.emboj.7600481","article-title":"The E2F family: specific functions and overlapping interests.","volume":"23","author":"Attwooll","year":"2004","journal-title":"EMBO J"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.ejca.2005.08.005","article-title":"Involvement of E2F transcription factor family in cancer.","volume":"41","author":"Tsantoulis","year":"2005","journal-title":"Eur J Cancer"},{"key":"R9-20250504","first-page":"5790416","article-title":"Comprehensive analysis of the expression and prognosis for E2Fs in human clear cell renal cell carcinoma.","volume":"2021","author":"Zhang","year":"2021","journal-title":"J Healthc Eng"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"831329","DOI":"10.3389\/fcell.2022.831329","article-title":"Differential expression of E2F transcription factors and their functional and prognostic roles in human prostate cancer.","volume":"10","author":"Han","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ymthe.2019.03.019","article-title":"RETRACTED: comprehensive analysis of the expression and prognosis for E2Fs in human breast cancer.","volume":"27","author":"Sun","year":"2019","journal-title":"Mol Ther"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fonc.2019.00161","article-title":"E2F2\/5\/8 serve as potential prognostic biomarkers and targets for human ovarian cancer.","volume":"9","author":"Zhou","year":"2019","journal-title":"Front Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","article-title":"Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.","volume":"28","author":"Lee","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER20 for analysis of tumor-infiltrating immune cells.","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses.","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e27633","DOI":"10.2196\/27633","article-title":"Web-based survival analysis tool tailored for medical research (KMplot): development and implementation.","volume":"23","author":"Lanczky","year":"2021","journal-title":"J Med Internet Res"},{"key":"R17-20250504","first-page":"A68","article-title":"The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge.","volume":"19","author":"Tomczak","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: an integrated repository portal for tumor-immune system interactions.","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinformatics"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends.","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrc2696","article-title":"Emerging roles of E2Fs in cancer: an exit from cell cycle control.","volume":"9","author":"Chen","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"585034","DOI":"10.3389\/fimmu.2020.585034","article-title":"Identification of immune cell infiltration and immune-related genes in the tumor microenvironment of glioblastomas.","volume":"11","author":"Huang","year":"2020","journal-title":"Front Immunol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","article-title":"Tumor infiltrating lymphocytes in ovarian cancer.","volume":"16","author":"Santoiemma","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.4161\/cc.9.13.12061","article-title":"Checks and balances: E2F-microRNA crosstalk in cancer control.","volume":"9","author":"Emmrich","year":"2010","journal-title":"Cell Cycle"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s13277-015-4770-7","article-title":"E2F1: a promising regulator in ovarian carcinoma.","volume":"37","author":"Zhan","year":"2016","journal-title":"Tumour Biol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1158\/1078-0432.CCR-07-1539","article-title":"E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.","volume":"13","author":"Huang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/PAI.0b013e3181d245c0","article-title":"Predicting malignant potential of gastrointestinal stromal tumors: Role of p16 and E2F1 expression.","volume":"18","author":"Tetikkurt","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3748\/wjg.v19.i21.3189","article-title":"E2F transcription factors and digestive system malignancies: how much do we know?","volume":"19","author":"Xanthoulis","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R31-20250504","first-page":"7802","article-title":"Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F.","volume":"13","author":"Ivey-Hoyle","year":"1993","journal-title":"Mol Cell Biol"},{"key":"R32-20250504","first-page":"2150","article-title":"E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.","volume":"21","author":"Xie","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/CBM-160196","article-title":"E2F3 transcription factor: a promising biomarker in lung cancer.","volume":"19","author":"Al Ahmed","year":"2017","journal-title":"Cancer Biomark"},{"key":"R34-20250504","first-page":"1","article-title":"[Analysis of the correlation between E2F3 expression and the number of tumor-infiltrating CD8(+)T cells in invasive bladder cancer tissues].","volume":"34","author":"Wang","year":"2018","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"R35-20250504","first-page":"1492","article-title":"MiR-194-5p inhibits cell migration and invasion in bladder cancer by targeting E2F3.","volume":"23","author":"Wang","year":"2018","journal-title":"J BUON"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1038\/s41388-021-01878-3","article-title":"Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair.","volume":"40","author":"Zhang","year":"2021","journal-title":"Oncogene"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2015.11.009","article-title":"Cancer immune contexture and immunotherapy.","volume":"39","author":"Becht","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s40425-019-0700-3","article-title":"PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.","volume":"7","author":"Beyrend","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1080\/15384101.2016.1234551","article-title":"Novel functions for the transcription factor E2F4 in development and disease.","volume":"15","author":"Hsu","year":"2016","journal-title":"Cell Cycle"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"152880","DOI":"10.1016\/j.prp.2020.152880","article-title":"Protein expression profiles and prognostic value of E2F family members in clear cell renal cell carcinoma.","volume":"216","author":"Kim","year":"2020","journal-title":"Pathol Res Pract"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1098-2388(200007\/08)19:1<3::AID-SSU2>3.0.CO;2-S","article-title":"Ovarian cancer: epidemiology, biology, and prognostic factors.","volume":"19","author":"Holschneider","year":"2000","journal-title":"Semin Surg Oncol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3748\/wjg.v17.i4.470","article-title":"A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma.","volume":"17","author":"Jiang","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R43-20250504","first-page":"5415","article-title":"E2F5 as an independent prognostic factor in esophageal squamous cell carcinoma.","volume":"33","author":"Ishimoto","year":"2013","journal-title":"Anticancer Res"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.cellsig.2017.09.022","article-title":"E2F6 protein levels modulate drug induced apoptosis in cardiomyocytes.","volume":"40","author":"Major","year":"2017","journal-title":"Cell Signal"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"116649","DOI":"10.1016\/j.lfs.2019.116649","article-title":"E2F6-mediated lncRNA CASC2 down-regulation predicts poor prognosis and promotes progression in gastric carcinoma.","volume":"232","author":"Li","year":"2019","journal-title":"Life Sci"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/1535-7163.MCT-14-0243","article-title":"miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.","volume":"13","author":"Tang","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3892\/or.2015.3812","article-title":"MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7.","volume":"33","author":"Li","year":"2015","journal-title":"Oncol Rep"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1093\/nar\/gky657","article-title":"Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.","volume":"46","author":"Clements","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1093\/nar\/gki855","article-title":"Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription.","volume":"33","author":"Christensen","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"djv151","DOI":"10.1093\/jnci\/djv151","article-title":"E2F8 as a novel therapeutic target for lung cancer.","volume":"107","author":"Park","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R51-20250504","first-page":"1","article-title":"How reciprocal interactions between the tumor microenvironment and ion transport proteins drive cancer progression.","volume":"182","author":"Elingaard-Larsen","year":"2022","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-020-02746-x","article-title":"Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40\/CD40L on dendritic cells.","volume":"70","author":"Sadeghlar","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"706286","DOI":"10.3389\/fcell.2021.706286","article-title":"Tumor associated macrophages, as the dominant immune cells, are an indispensable target for immunologically cold tumor-glioma therapy?","volume":"9","author":"Tong","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer.","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:15:04Z","timestamp":1746328504000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035722","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]}}}